BioSpace News Archive

Hemogenyx Pharmaceuticals plc, the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress.

Amarna Therapeutics, a privately-held biotechnology company focused on developing transformative gene therapies for a range of rare and prevalent genetic diseases, including Type 1 Diabetes Mellitus, is pleased to announce the formation of its new Scientific Advisory Board. The newly established SAB consists of seven distinguished international scientific opinion leaders.

Ovid Therapeutics Inc., a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, reports that Takeda Pharmaceutical Company Limited has announced topline data from its Phase 3 SKYLINE and SKYWAY studies evaluating soticlestat for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.

EyePoint Pharmaceuticals, Inc. today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

Kraig Biocraft Laboratories, Inc., announces that it has successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids.

Natera, Inc. today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant patients.

IMFINZI ® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer.

The Berlin Heals Holding AG has developed the C-MIC device, a revolutionary and life-saving treatment for patients with heart failure.

Grifols announced that Biotest, a Grifols Group company, has received approval from the United States Food and Drug Administration for Yimmugo®, an innovative intravenous immunoglobulin therapeutic, to treat primary immunodeficiencies.

Things aren’t always as they seem. Take pancreatic cancer, for example. In up to one in 10 cases, researchers have documented a peculiar characteristic.